Salmonid yersiniosis: vaccination still requires surveillance

Enteric redmouth disease remains an important cause of losses in salmonid farming despite the availability of effective vaccines. Yersinia ruckeri should therefore be treated neither as an unavoidable problem managed only with antibiotics nor as a risk erased by routine vaccination. Experimental evidence and field surveillance show that protection depends on bacterial strain and biotype, administration route, timing, temperature and fish condition. Disease in a vaccinated group calls for a complete investigation, not an automatic diagnosis of “vaccine failure.”

Recognising a compatible syndrome

Acute disease in rainbow trout may involve lethargy, anorexia, darkening, exophthalmia and haemorrhage around the mouth, in the oral cavity, at fin bases or internally. None of these signs is constant or specific. Carriers and chronically infected fish may have few external changes, while other bacterial septicaemias produce a similar picture.

Context strengthens the examination: mortality pattern, temperature change, grading, transfer, density, reduced dissolved oxygen, fish origin and vaccination record. Moribund, untreated fish that represent the affected group should be sampled promptly for bacteriology. Delayed collection from decomposing carcasses or sampling after antimicrobial treatment substantially weakens interpretation.

Bacterial culture and isolate identification remain important to confirm Y. ruckeri and to perform susceptibility testing if treatment is being considered. PCR may speed up or complement identification, but a molecular signal alone does not prove that the bacterium caused the lesions and mortality. History, necropsy and, where appropriate, histopathology support the differential diagnosis.

Why vaccinated fish may still become ill

Earlier vaccines mainly targeted serotype O1, biotype 1. Outbreaks caused by non-motile biotype 2 strains were subsequently reported in vaccinated farms. Broader formulations have improved coverage, but the word “vaccinated” never describes the covered strain, duration of immunity or administration quality by itself.

Timing also matters. In a controlled rainbow-trout study published in 2013, mortality three months after challenge was 76% in controls, 37% after one immersion, 4% after two immersions, 2% after injection and 0% after immersion followed by injection. At seven months, the single-immersion group was no longer protected in that experimental model. These figures compare protocols under specific challenge conditions; they are not farm-level guarantees.

Water temperature affects immune development. A 2008 experiment found protection after bath vaccination at 15°C but not at 5°C or 25°C under its conditions. Farms should not convert those three points into universal cut-offs. They show why degree-days, fish size, acclimation and the authorised product instructions must be respected.

The March 2025 UK summary of product characteristics for one bivalent vaccine provides a useful concrete example: onset at 336 degree-days, a primary 30-second immersion for fish of at least 5 g, and an intraperitoneal booster under anaesthesia for fish of at least 12 g. It also specifies clean, oxygenated hatchery water and avoidance of stress and temperature differences. These directions apply to that authorised product and jurisdiction, not to every vaccine.

Investigating an outbreak after vaccination

The investigation starts by reconstructing the programme: product, batch, storage, dilution, bath volume, exposure time, fish biomass and size, water temperature, degree-days, booster and handling events. A correct prescription can still be poorly delivered if biomass is underestimated, solution is reused beyond instructions or fish are stressed during administration.

The laboratory should retain isolates when possible and report identification at an informative level. Epidemiological links between units, incoming stocks and prior cases help distinguish persistence, introduction and operational failure. A recent study of naturally infected rainbow trout documents immune responses during Y. ruckeri infection, but immune markers are not yet a substitute for routine farm diagnosis.

Antimicrobial treatment may be justified for a confirmed bacterial outbreak under veterinary oversight and local rules. Culture and susceptibility testing should guide selection where feasible. Treatment does not correct low oxygen, excessive density, chronic handling stress or contaminated equipment. Those drivers can sustain mortality and promote recurrence.

Build layered prevention

Vaccination belongs in a wider biosecurity programme: known-source fish and eggs, managed quarantine, unit separation, dedicated or validated equipment, mortality removal, water-quality monitoring and traceable movements. Staff need a clear threshold for reporting appetite loss or abnormal mortality before losses accelerate.

Performance should be reviewed by cohort. Record survival, clinical episodes, diagnostics, temperatures, product and protocol. Comparing like cohorts over time is more useful than treating the vaccinated/unvaccinated field as a complete explanation. Unexpected cases should trigger learning without assuming either that the vaccine is useless or that husbandry alone caused the event.

Vetofish can help design sampling, review vaccination delivery, interpret isolates and identify environmental or movement-related risks. The practical goal is layered control: a vaccine matched to the threat, delivered under validated conditions, and supported by surveillance capable of detecting what vaccination does not prevent.